Navigation Links
Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
Date:12/5/2007

Findings reinforce the benefits of Asacol for ulcerative colitis patients

AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an effective and well-tolerated treatment for patients with all extents of ulcerative colitis (UC), including isolated proctitis. The results showed that patients with isolated proctitis who took Asacol, dosed at 2.4 g/day for six weeks, experienced significant improvement as early as three weeks, and sustained improvement at six weeks, of UC symptoms. At six weeks 83 percent of patients had improvement in rectal bleeding, 75 percent had mucosal healing and 57 percent had reduced stool frequency. These data were presented today at the Crohn's & Colitis Foundation of America's (CCFA) National Research and Clinical Conference/Sixth Annual Advances in the Inflammatory Bowel Diseases (IBD) Meeting.

Treatment of UC patients is impacted by the fact that most patients would choose oral therapy over other routes of delivery, such as rectal therapy(1). However, approximately 30 percent of UC patients have isolated proctitis(2), a condition that is thought to be a challenge to treat with oral medication alone.

"A common misperception among physicians is that all oral 5-ASA studies have included proctitis patients; however, this is not the case," says Dr. Seymour Katz, Clinical Professor of Medicine at the New York University School of Medicine. "The positive findings from these Asacol studies reassure physicians that Asacol is one treatment that has been proven effective throughout the entire colon, even the most distal portions, and should help guide physicians how to effectively treat their UC patients."

Additional Study Details

Data from two Phase III, multi-center, randomized, double-blind, 6-week, active-controlled studies of similar design (ASCEND
'/>"/>

SOURCE Procter & Gamble Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Roughly three-quarters of pharmacists ... substituting an interchangeable biosimilar for its branded biologic ... nonproprietary name, according to a survey published in ... Journal of Managed Care & Specialty Pharmacy (JMCP). ... of pharmacists would feel as confident if the ...
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... pre-clinical study published in the Proceedings of ... ) that showed when ibrutinib (IMBRUVICA ® ) ... inhibitor), suppression of tumor growth was enhanced suggesting ... certain hematologic cancers and solid tumors with the ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17
... DALLAS, Oct. 15 /PRNewswire-FirstCall/ -- ACCESS ... provided an update on its European commercial launch of ... debilitating side effect of radiation treatment and chemotherapy. ... five European countries, having been granted the CE mak ...
... Pharmaceuticals, Inc. announced today that new data confirm that ... of fat absorption in children aged 7-11 years who ... (CF). EPI is a condition resulting from a deficiency ... are necessary to digest nutrients in food. CREON® has ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 2CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 6
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... NB (PRWEB) February 28, 2015 ... center software suite for Asterisk, are pleased to announce ... highly successful 5.7 and 5.8 versions of Q-Suite, this ... well as a number of new features to the ... Q2 2015. , Q-Suite 5.9 will add features to ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Dr. ... Central Coast area residents, recently announced a special offer ... It’s a treatment option for new and established patients ... 2015 with a bright, white smile, Dr. Patel and ... of $299, marked down from the regular price of ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... PBM,s Lakeland, Florida Facility to Create 100 ... Jobs by End of 2010Watch the Tampa ... JOHNSON CITY, N.Y., March 12 Innovation, ... announced that WellDyneRx, a national pharmacy benefit ...
... 12 In honor of World Kidney Day, DaVita Inc., ... 2009 planned activities to help raise awareness and education about ... epidemic affecting 26 million adult Americans - 90% of whom ... several campaigns to help bridge the gap between those who ...
... Microsoft Corp. today,announced the call for ... Life,Sciences Innovation Awards, recognizing breakthroughs in the ... Pharmaceutical and Life Sciences,Innovation Awards provide an ... demonstrate their application of available software and ...
... to heed study,s finding and help fight obesity , , THURSDAY, ... other play areas may keep children more active and help ... , For every park found within a half-mile ... and a boy,s odds of taking part in leisure walking ...
... exposure to cold and flu virusesCLEVELAND, March 12 ... Postgraduate Medicine suggests that a strain of ... GBI-30, PTA-6086), increases the body,s immune response to viruses ... colds and flu. Study data showed significant increases ...
... Prevention (CoE) has received a grant from The California ... on providing culturally competent health care to trangender individuals. ... information that we will make available in order to ... transpeople. This grant will improve the quality of ...
Cached Medicine News:Health News:WellDyneRx Unveils Second Pharmacy Mail Service Facility Using Innovation's High Volume Prescription Dispensing Technology 2Health News:WellDyneRx Unveils Second Pharmacy Mail Service Facility Using Innovation's High Volume Prescription Dispensing Technology 3Health News:DaVita Raises Awareness on World Kidney Day 2Health News:DaVita Raises Awareness on World Kidney Day 3Health News:Microsoft's 2009 Pharmaceutical and Life Sciences Innovation Awards Call for Entries Now Open 2Health News:Microsoft's 2009 Pharmaceutical and Life Sciences Innovation Awards Call for Entries Now Open 3Health News:Kids Who Live Near Green Spaces Seem to Walk More 2Health News:New Study Shows Probiotic Strain Effective in Boosting Immune Response 2Health News:New Study Shows Probiotic Strain Effective in Boosting Immune Response 3Health News:New Study Shows Probiotic Strain Effective in Boosting Immune Response 4Health News:UCSF Transgender HIV Prevention Center funded to provide primary care information 2Health News:UCSF Transgender HIV Prevention Center funded to provide primary care information 3
Subretinal Aspiration Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 6.5mm, 27g (0.40); Angled at 60°, 2.5mm from Tip....
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: